CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS)

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Omalizumab to Accelerate a Symptom-driven Multi-food OIT	Food IgE-mediated Allergy; Immunotherapy; Omalizumab; Physiological Effects of Drugs	Active, not recruiting	Phase 2	2024-11-27		NCT04045301

Clinical trials